Abstract:Some women take medication during pregnancy to address a variety of clinical conditions. Because of ethical and logistical concerns, it is impossible to determine fetal drug exposure, and therefore fetal risk, during pregnancy. Hence, alternative approaches need to be developed to predict maternal-fetal drug exposure throughout pregnancy. To do so, we previously developed and verified a maternal-fetal physiologically based pharmacokinetic model, which can predict fetal exposure to drugs that passively cross the placenta. However, many drugs are actively transported by the placenta (e.g., human immunodeficiency virus protease inhibitors). To extend our maternal-fetal physiologically based pharmacokinetic model to these actively transported drugs, we determined the gestational age–dependent changes in the protein abundance of placental transporters. Total cellular membrane fractions from first trimester (T1; n = 15), second trimester (T2; n = 19), and term (n = 15) human placentae obtained from uncomplicated pregnancies were isolated by ultracentrifugation. Transporter protein abundance was determined by targeted quantitative proteomics using liquid chromatography tandem mass specrometry. We observed that breast cancer resistance protein and P-glycoprotein abundance significantly decreased from T1 to term by 55% and 69%, respectively (per gram of tissue). Organic anion–transporting polypeptide (OATP) 2B1 abundance significantly decreased from T1 to T2 by 32%. In contrast, organic cation transporter (OCT) 3 and organic anion transporter 4 abundance significantly increased with gestational age (2-fold from T1 to term, 1.6-fold from T2 to term). Serotonin transporter and norepinephrine transporter did not change with gestational age. The abundance of bile salt export pump, multidrug resistance-associated protein 1-5, Na+-taurocholate cotransporting polypeptide, OATP1B1, OATP1B3, OCTN1-2, concentrative nucleoside transporter 1-3, equilibrative nucleoside transporter 2, and multidrug and toxin extrusion 1 could not be quantified. These data can be incorporated into our maternal-fetal physiologically based pharmacokinetic model to predict fetal exposure to drugs that are actively transported across the placenta.SIGNIFICANCE STATEMENTWe quantified the protein abundance of key placental uptake and efflux transporters [organic cation transporter (OCT) 3, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP)] across gestational ages (first trimester, second trimester, and term) using quantitative targeted proteomics. We observed that the protein abundance of P-gp and BCRP decreased, whereas that of OCT3 increased with gestational age. Incorporating the protein abundance determined in this study into maternal-fetal physiologically based pharmacokinetic model can help us better predict fetal drug exposure to substrates of these transporters.

Differences in cytochrome p450 enzyme expression and activity in fetal and adult tissues

Expression and characteristics of cytochrome p-450 1, 2 and 3 in human fetal adrenals

Expression and regulation of human fetal-specific CYP3A7 in mice.

Changes of Multiple Biotransformation Phase I and Phase II Enzyme Activities in Human Fetal Adrenals During Fetal Development

Developmental Regulation of CYP3A4 and CYP3A7 in Chinese Han Population.

Effects Of Intrauterine Undernutrition On The Expression Of Cyp3a23/3a1, Pxr, Car And Hnf4 Alpha In Neonate Rats

Enzymic Differentiation of Human Liver: Comparison with the Rat Model

Developmental expression of catecholamine system in the human placenta and rat fetoplacental unit

Absolute Membrane Protein Abundance of P-gp, BCRP and MRPs in Term Human Placenta Tissue and Commonly Used Cell Systems: Application in PBPK Modeling of Placental Drug Disposition

Study on Tissue Distribution Difference of Cytochrome P450 2C19 in Chinese Population Han

The effect of pregnancy-related hormones on hepatic transporters: studies with premenopausal human hepatocytes

Comparison of Hepatic Metabolite Profiles between Infant and Adult Male Mice Using 1H-NMR-Based Untargeted Metabolomics

Ontogeny of drug metabolism enzymes and epigentic regulation

Expression of CYP3A23/1, CYP3A2, PXR, CAR and HNF4alpha in Large-for-gestational-age Neonatal Rats.

Tissue Distribution and Gender-Specific Protein Expression of Cytochrome P450 in five Mouse Genotypes with a Background of FVB

RNA Sequencing Reveals Dynamic Changes of Mrna Abundance of Cytochromes P450 and Their Alternative Transcripts During Mouse Liver Development

Gestational Age–Dependent Abundance of Human Placental Transporters as Determined by Quantitative Targeted Proteomics

Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.

Real-time fluorometric evaluation of hepatoblast proliferation in vivo and in vitro using the expression of CYP3A7 coding for human fetus-specific P450

Transcriptomic comparison of in vitro models of the human placenta

Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells